PolyPeptide Studies Strategic Options as Private Equity Circles

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000PolyPeptide Group AG and its billionaire shareholder Frederik Paulsen are working on strategic options for the company. The Swiss contract drugmaker’s review is at an early stage and “there can be no assurances” that it will result in any transaction or other outcome, the company said in a statement on Tuesday. PolyPeptide said it is “well positioned” to achieve its ambition to double 2023 revenue by 2028.